In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec.
HIV
MSM
PrEP
clustering
network
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
14
02
2019
accepted:
14
02
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
A better understanding of HIV transmission dynamics among populations at high risk is important for development of prevention strategies. We determined HIV transmission networks from infected individuals enrolled in the pre-exposure prophylaxis (PrEP) IPERGAY trial in combination with the ANRS PRIMO and Montreal PHI cohorts to identify and characterize active clusters of transmission in this high-risk population. Genotypic resistance tests were performed on plasma samples from 31 IPERGAY participants. Reverse transcriptase sequences were analyzed in combination with unique HIV Overall, 1893 participants were included. Transmission network analyses revealed that 14 individuals (45.2%) from the IPERGAY trial were involved in 13 clusters sampled over a median period (interquartile range) of 2 (0.3-7.8) years, including 7 dyads and 6 larger clusters ranging from 4 to 28 individuals. When comparing characteristics between clustering individuals enrolled in the PRIMO cohort (n = 377) and in IPERGAY (n = 14), we found that IPERGAY participants had a higher viral load (5.93 vs 5.20 log These results demonstrate high rates of HIV transmission clustering among young high-risk MSM enrolled in the IPERGAY trial. In-depth sampling of high-risk populations may help to uncover unobserved transmission intermediaries and improve prevention efforts that could be targeted to the most active clusters.
Sections du résumé
BACKGROUND
BACKGROUND
A better understanding of HIV transmission dynamics among populations at high risk is important for development of prevention strategies. We determined HIV transmission networks from infected individuals enrolled in the pre-exposure prophylaxis (PrEP) IPERGAY trial in combination with the ANRS PRIMO and Montreal PHI cohorts to identify and characterize active clusters of transmission in this high-risk population.
METHODS
METHODS
Genotypic resistance tests were performed on plasma samples from 31 IPERGAY participants. Reverse transcriptase sequences were analyzed in combination with unique HIV
RESULTS
RESULTS
Overall, 1893 participants were included. Transmission network analyses revealed that 14 individuals (45.2%) from the IPERGAY trial were involved in 13 clusters sampled over a median period (interquartile range) of 2 (0.3-7.8) years, including 7 dyads and 6 larger clusters ranging from 4 to 28 individuals. When comparing characteristics between clustering individuals enrolled in the PRIMO cohort (n = 377) and in IPERGAY (n = 14), we found that IPERGAY participants had a higher viral load (5.93 vs 5.20 log
CONCLUSIONS
CONCLUSIONS
These results demonstrate high rates of HIV transmission clustering among young high-risk MSM enrolled in the IPERGAY trial. In-depth sampling of high-risk populations may help to uncover unobserved transmission intermediaries and improve prevention efforts that could be targeted to the most active clusters.
Identifiants
pubmed: 30899768
doi: 10.1093/ofid/ofz080
pii: ofz080
pmc: PMC6422434
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz080Subventions
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI131971
Pays : United States
Références
Virology. 1999 Dec 20;265(2):218-25
pubmed: 10600594
Bioinformatics. 2000 Jun;16(6):562-3
pubmed: 10980155
Mol Biol Evol. 2002 May;19(5):708-17
pubmed: 11961104
Proc Biol Sci. 2003 Jun 7;270(1520):1123-8
pubmed: 12816649
Bioinformatics. 2005 Jan 15;21(2):260-2
pubmed: 15377507
J Mol Evol. 1992 Feb;34(2):126-9
pubmed: 1556748
AIDS Res Hum Retroviruses. 2005 Jan;21(1):98-102
pubmed: 15665649
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
J Infect Dis. 2011 Nov;204(9):1463-9
pubmed: 21921202
PLoS One. 2012;7(2):e31695
pubmed: 22348121
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
J Acquir Immune Defic Syndr. 2013 May 1;63(1):135-41
pubmed: 23364512
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
Curr HIV/AIDS Rep. 2014 Mar;11(1):81-92
pubmed: 24384832
PLoS One. 2014 Jun 05;9(6):e98443
pubmed: 24901437
AIDS Res Hum Retroviruses. 2014 Dec;30(12):1226-35
pubmed: 25275430
JAMA Intern Med. 2015 Apr;175(4):588-96
pubmed: 25706928
PLoS One. 2015 Aug 12;10(8):e0135367
pubmed: 26267615
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Lancet HIV. 2016 May;3(5):e231-8
pubmed: 27126490
AIDS. 2017 Mar 13;31(5):707-717
pubmed: 28005684
PLoS Pathog. 2017 Jan 9;13(1):e1006000
pubmed: 28068413
Retrovirology. 2017 Feb 21;14(1):15
pubmed: 28222757
J Infect Dis. 2017 Aug 1;216(3):382-386
pubmed: 28666370
Viruses. 2017 Dec 28;10(1):
pubmed: 29283390
BMC Public Health. 2018 Aug 16;18(1):1020
pubmed: 30115056
Mol Biol Evol. 1993 May;10(3):512-26
pubmed: 8336541